Company profilePharmaceutical#915 of 1,318 in Pakistan✓ No DRAP alerts

Nouveaux Pharma Limited DSL: 071

Pharmaceutical company · 5 brands · 7 molecules

Ranked #12 of 15 companies in Immunosuppressants

5 registered products 7 pharmaceutical brands 7 distinct molecules 0 DRAP alerts

Company overview

5
registered products
7
pharmaceutical brands
7
distinct molecules
1
therapeutic classes
0
DRAP alerts

Nouveaux Pharma Limited DSL: 071 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 5 product registrations across 7 distinct molecules. Its portfolio is concentrated in Immunosuppressants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Nouveaux

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

3
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20263

Top molecules by brand count

Ciclosporin ...... 100 Mg Mg1 brand
Octreotide ...... 20 Mg1 brand
Octreotide ...... 10 Mg1 brand
Octreotide ...... 30 Mg1 brand

Therapeutic classes

Immunosuppressants · 1

Conditions treated

Auto Immune Disease · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official5 products · Rs 10,301.78 – Rs 237,754.57
Servaid1 products · Rs 5,164.6 – Rs 5,164.6
Median across source: Rs 131,798.95

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

ALLMED LABORATORIES holds 62 molecules not in this portfolio
AlbuterolArtemetherArtesunateAscorbic AcidAzithromycinCalcium
BIOCARE PHARMACEUTICAL holds 11 molecules not in this portfolio
AzithromycinCefoperazoneColistimethate SodiumColistinFluconazoleInterferon Alfa-2B
Hoffmann Human Health Pakistan Ltd. DSL: 05-352-0065-013785D holds 4 molecules not in this portfolio
CyclosporineIohexolLignocaine InjectionPurified Hepatitis-B Surface Antigen

Get the full profile for Nouveaux

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.